NCT01072799View on ClinicalTrials.gov

Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

4,560

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Seasonal Influenza
Interventions
BIOLOGICAL

Placebo

Two doses (Day 1 and Day 22); 0.5mL

BIOLOGICAL

A/H1N1 2009 Influenza VLP Vaccine

Two doses (Day 1 \& Day 22); 0.5mL

Trial Locations (1)

C.P 06720

"Specialities Hospital, National Medical Centre Siglo XXI Mexican Institute for Social Security (IMSS)", Mexico City

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
collaborator

Instituto Mexicano del Seguro Social

OTHER_GOV

lead

Novavax

INDUSTRY